Results 51 to 60 of about 14,856,300 (187)

HLA-DR Helps to Differentiate Erythrodermic Cutaneous T-cell Lymphoma from Erythrodermic Inflammatory Dermatoses in Flow Cytometry

Acta Dermato-Venereologica, 2023
Differential diagnosis of erythroderma is challenging in dermatology, especially in differentiating erythrodermic cutaneous T-cell lymphoma from erythrodermic inflammatory dermatoses.
Jingru Sun, Ran You, Beini Lyu, Xueying Li, Yumei Gao, Yujie Wen, Chenxue Qu, Yang Wang   +7 more
doaj   +1 more source

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma:a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.

, 2009
Among 1153 new adult cases of peripheral/T-cell lymphoma from 1990-2002 at 22 centers in 13 countries, 136 cases (11.8%) of extranodal natural killer (NK)/T-cell lymphoma were identified (nasal 68%, extranasal 26%, aggressive/unclassifiable 6%).
Tanin Intragumtornchai, Won Seog Kim, Ivy Sng, Wing yan Au, PILERI, STEFANO, Dennis D. Weisenburger, ZINZANI, PIER LUIGI, Julie Vose, James O. Armitage, Shigeo Nakamura   +9 more
core   +1 more source

Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study

eJHaem
Objective We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed/ refractory T‐cell lymphoma. Methods A dose escalation study design was utilized.
Carrie van der Weyden, Mathias Bressel, Amit Khot, Henry Miles Prince, Michael Dickinson   +4 more
doaj   +1 more source

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin’s lymphoma and T-cell non-Hodgkin’s lymphoma

Haematologica, 2011
We recently reported deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Functional analyses confirmed that PTPN2 acts as classical tumor suppressor repressing the proliferation of T cells, in part through ...
Maria Kleppe, Thomas Tousseyn, Eva Geissinger, Zeynep Kalender Atak, Stein Aerts, Andreas Rosenwald, Iwona Wlodarska, Jan Cools   +7 more
doaj   +1 more source

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]

, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Renné Christoph, Benz Alexander H, Hansmann Martin L, Christoph, Renné, Benz, Alexander, Hansmann, Martin-Leo   +5 more
core   +1 more source

Peripheral T-cell lymphoma, not otherwise specified

Journal of Family Medicine and Primary Care, 2017
The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct ...
Kunal Kishor Jha, Suresh K Gupta, Harpreet Saluja, Nuwadatta Subedi   +3 more
doaj   +1 more source

Transformationspotential von NPM-ALK, p21SNFT und Tax in Reifen T Lymphozyten [PDF]

, 2010
To date it is not clear at which stage of differentiation mature T cell leukaemia/lymphoma is initiated. Previous studies in our group showed that mature T cells are relatively resistant to transformation.
Kumar, Ashok
core  

Peripheral T Cell Non-Hodgkin’s Lymphoma following Treatment of Hodgkin’s Lymphoma

Case Reports in Oncological Medicine, 2015
Previous reports have suggested that non-Hodgkin’s lymphoma (NHL) is more likely to develop in patients with Hodgkin lymphoma (HL) compared to the general population. These two can occur synchronously or metachronously.
Sun Hee Chang, Hye Ran Lee
doaj   +1 more source

Anaplastic large-cell lymphoma.

, 2011
The concept of anaplastic large-cell lymphoma (ALCL) has changed over the years because of a stream of new information and novel understanding regarding the cell of origin, biology, genetics, and clinical features of these neoplasms. This new information
European T. Cell Lymphoma Study Group, Pileri SA, FACCHETTI, Fabio, Inghirami G   +3 more
core   +1 more source

Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas

Leukemia Research Reports
Brentuximab vedotin (BV) has demonstrated efficacy against CD30+ peripheral T-cell lymphoma (PTCL). We herein report a case of CD30+ peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) that emerged one month after completing BV ...
Gen Hasegawa, Noriharu Nakagawa, Yoshimichi Ueda, Masahide Yamazaki   +3 more
doaj   +1 more source